Obicetrapib Drug Asset Due Diligence Report 2026

This Obicetrapib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

NDA/BLA

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Obicetrapib can convert its Small molecule drug profile and CETP biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Obicetrapib (query alias: obicetrapib)
Modality / target	Small molecule drug; CETP; CETP inhibitors
Highest global status	NDA/BLA
Originator	Tanabe Pharma Corp.
Active developers	NewAmsterdam Pharma Holding BV, NewAmsterdam Pharma Corp., NewAmsterdam Pharma Co. NV

The MCP disease footprint includes Primary hypercholesterolemia, Diabetes Mellitus, Type 2, Hyperlipidemias. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07219602	Phase 3	Recruiting	300	The percent change from Baseline to Day 84 in LDL-C compared with placebo for the following treatment groups: - obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group; and - obicetrapib 10 mg monotherapy treatment group
NCT06982508	Phase 2	Recruiting	100	Sum of Percent Change of Antioxidant Levels within HDL
NCT06496243	Phase 2	Recruiting	69	To evaluate the effect of evolocumab in combination with obicetrapib on lipoprotein (a) (Lp[a]).

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

Phase 3; n=354; evaluation: Positive. Reported fields: LDL-C(84-day change): Difference (%) = -36.3(95.0% CI, -42.2 to -30.4), P-Value = < 0.0001; LDL-C(84-day change): Difference (%) = -36.3(95.0% CI, -42.2 to -30.4), P-Value = < 0.0001

A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed Dose Combination Daily on Top of Maximally Tolerated Lipid-Modifying Therapy in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) and/or Atherosclerotic Cardiovascular Disease (ASCVD) or Multiple ASCVD Risk Factors

Phase 3; n=407; evaluation: not stated. Reported fields: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C(Least Squares Mean) = 3.03 percent change from baseline (Standard Error, 3.564); Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C(Least Squares Mean): Least Squares (LS) Means = -48.61(95% CI, -58.33 to -38.89), P-Value = <.0001; Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C(Least Squares Mean): Least Squares (LS) Means = -48.61(95% CI, -58.33 to -38.89), P-Value = <.0001

Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease

Phase 3; n=1535; evaluation: Positive. Reported fields: P-tau217(12-month) = 4.94 % ; P-tau217(12-month) = 2.09 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Obicetrapib addresses Primary hypercholesterolemia, Diabetes Mellitus, Type 2, Hyperlipidemias. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2022-06-28	NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe	Phase 3	US$150.5M upfront; US$911.4M milestones; US$1,061.9M stated total
2020-08-25	NewAmsterdam Pharma Acquires Obicetrapib from Amgen	Phase 2	Financial terms not disclosed
2013-01-22	Dezima Pharma In-Licenses CETP Inhibitor Program From Mitsubishi Tanabe Pharma Corporation	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions”. The milestone feed surfaced a patent-application signal described as “Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (HEFH) and/or atherosclerotic cardiovascular disease (ASCVD)”. The milestone feed surfaced a patent-application signal described as “Treatment and prevention of age-related macular degeneration using a CETP inhibitor”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO